T1	Participants 110 172	urogenital atrophy in postmenopausal women on hormone therapy.
T2	Participants 802 859	27 women with climacteric symptoms and atrophic vaginitis
T3	Participants 1225 1266	receive HT plus local estriol or placebo.
